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Normative modelling is an emerging method for quantifying how individuals 
deviate from the healthy populational pattern. Several machine learning models 
have been implemented to develop normative models to investigate brain 
disorders, including regression, support vector machines and Gaussian process 
models. With the advance of deep learning technology, the use of deep neural 
networks has also been proposed. In this study, we assessed normative models 
based on deep autoencoders using structural neuroimaging data from patients 
with Alzheimer’s disease (n=206) and mild cognitive impairment (n=354). We first 
trained the autoencoder on an independent dataset (UK Biobank dataset) with 
11,034 healthy controls. Then, we estimated how each patient deviated from this 
norm and established which brain regions were associated to this deviation. 
Finally, we compared the performance of our normative model against traditional 
classifiers. As expected, we found that patients exhibited deviations according to 
the severity of their clinical condition. The model identified medial temporal 
regions, including the hippocampus, and the ventricular system as critical regions 
for the calculation of the deviation score. Overall, the normative model had 
comparable cross-cohort generalizability to traditional classifiers. To promote 
open science, we are making all scripts and the trained models available to the 
wider research community. 
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Normative modelling is an emerging method for quantifying and describing 
how individuals deviate from the expected pattern learned from a population or 
large sample 1. Recently, this approach has been applied to neuroimaging data 
to investigate a number of brain disorders, such as attention deficit hyperactivity 
disorder 2,3, autism spectrum disorder 4,5, schizophrenia 3,5,6 and dementia 7,8. The 
procedure of normative modelling used in these studies has two steps: (i) first, 
statistical models are estimated to characterise the typical brain data from a 
reference cohort; (ii) then, the estimated model is applied to a target clinical 
cohort in order to quantify the variation (e.g. due to the effect of brain disorders). 
Many statistical models have been proposed for normative modelling, 
including regression, support vector machines and Gaussian process modelling 
(for an extensive list, see Marquand et al., 2019). In Pinaya et al. 5, we proposed 
a normative modelling approach based on the use of deep autoencoders to 
evaluate psychiatric patients. The use of a deep learning approach 10,11 enables 
models to learn multiple levels of representation about the intricate structure of 
the data and identify the most important morphological characteristic of the 
healthy brain. In addition, in Pinaya et al. 5, the models were able to detect 
deviations at the level of the individual, with patients with schizophrenia and 
patients with autism spectrum disorder presenting values significantly higher than 
the healthy controls (HC).  
Similar to psychiatric disorders, the clinical interpretation of magnetic 
resonance imaging scans can be challenging in the context of neurodegenerative 
disorders, as brain alterations may be difficult to distinguish from those related to 
healthy ageing. The identification of disease-related alterations can be 
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particularly tricky in the early stages of a disorder. For this reason, there is a 
grown interest in the development of methods for quantifying deviations of 
regional brain volumes that can discriminate between healthy and pathological 
ageing, with the ultimate aim of improving diagnostic and prognostic assessment 
of neurodegenerative disorders 12. Here, we used the autoencoder normative 
method 5 to evaluate the most common type of dementia in the elderly worldwide, 
Alzheimer’s disease (AD). 
First, we trained the normative models using a large number of HC 
subjects (> 11,000 participants). Then, we assessed the performance of these 
models using data from patients with a diagnosis of mild cognitive impairment 
(MCI), the prodromal stage to AD, and patients with a diagnosis of AD. This 
assessment involved calculating the deviation, i.e. the extent to which subjects 
deviate from the norm, in five additional datasets composed of patients with MCI, 
patients with AD, and HC subjects. We had two main hypotheses. First, we 
hypothesised that the normative models would be robust and sensitive enough 
to create deviation values that reflect the severity of the brain anatomical 
alterations due to the disease, i.e. individuals with AD would deviate from 
normality more than those with MCI. Second, we hypothesised that the main brain 
regions driving the observed deviation would include the medial temporal cortex 
and the ventricular system, consistent with the results of previous neuroimaging 
studies of MCI and AD 13,14. Finally, we compared the performance of the 
normative approach against traditional classifiers to discriminate the patient 





In our analysis, we used six datasets: the UK Biobank 15, the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) 16, the Australian Imaging Biomarkers 
and Lifestyle Study of Ageing (AIBL) 17, the Alzheimer’s Disease Repository 
Without Borders (ARWiBo) 18,19, the Open Access Series of Imaging Studies: 
Cross-Sectional (OASIS-1) 20, and the Minimal Interval Resonance Imaging in 
Alzheimer's Disease (MIRIAD) 21.  
The UK Biobank is a study that aims to follow the health and well-being of 
500,000 volunteer participants across the United Kingdom. From these 
participants, a subsample was chosen to collect multimodal imaging, including 
structural neuroimaging. Here, we used an early release of the project’s data 
comprising of 11,034 HC participants. The inclusion criteria for the present study 
were: a) subjects who had the data collected in the same MRI scanner (from 
Cheadle centre), b) age between 47 to 73 years old. The only exclusion criterion 
was previous hospitalization associated with the diagnosis of mental and 
behavioural disorders, disease of the nervous system, cerebrovascular diseases, 
benign neoplasm of meninges, brain and other parts of the central nervous 
system, or injuries to the head. This study (UK Biobank project #40323) was 
covered by the general ethical approval for UK Biobank studies from the NHS 
National Research Ethics Service on 17th June 2011 (Ref 11/NW/0382). All 
methods were carried out in accordance with the approved guidelines and 
regulations. All UK Biobank participants provided written informed consent. More 
details about the dataset can be found elsewhere 15,22–24. 
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The ADNI consortium started in 2003 as a public-private partnership, led 
by Principal Investigator Michael W. Weiner. Its goal was to verify whether 
different neuroimaging biomarkers and neuropsychological assessments can be 
combined to measure the progression of MCI and to study the development of 
AD. All ADNI participants provided written informed consent, and study protocols 
were approved by each local site’s institutional review board. All methods were 
carried out in accordance with the approved guidelines. Further information about 
ADNI, including full study protocols, complete inclusion and exclusion criteria, 
and data collection and availability can be found at http://www.adni-info.org/. All 
methods as stated on the website were performed with the relevant guidelines 
and regulations. In this study, we included the structural MRI collected during the 
ADNI GO, ADNI 2 and ADNI 3 phases. Similar to UK Biobank, we included only 
subjects with age between 47 to 73 years old. The final dataset comprised of 517 
subjects, where 212 were HC, 159 were patients with early MCI (EMCI), 82 were 
patient with late MCI (LMCI), and 64 were patients with AD. In the ADNI datasets, 
participants were assigned to these MCI stages based on different levels of 
impairment on a single episodic memory measure, with the EMCI group showing 
milder episodic memory impairment than the LMCI group 25,26. 
The AIBL dataset was developed to enhance the understanding of the 
pathogenesis of AD, concentrating on its early diagnosis (more details can be 
found in Ellis et al., 2009). Ethics approval for the AIBL study and all experimental 
protocols was provided by the ethics committees of Austin Health, St Vincent’s 
Health, Hollywood Private Hospital and Edith Cowan University. All experiments 
and methods were carried out in accordance with the approved guidelines and 
regulations and all volunteers gave written informed consent before participating 
7 
 
in the study. Here, we included the structural MRI of subjects between 47 to 73 
years old, to match the age range of the UK Biobank dataset. The final group was 
composed of 346 subjects, where 262 were HC, 46 were patients with MCI (stage 
not known), and 38 were patients with AD. 
The ARWiBo is a cross-sectional dataset including data from patients and 
controls enrolled at the Scientific Institute for the Research and Care of 
Alzheimer’s Disease [Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) 
Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy]. A multidisciplinary 
team of neurologists, neuroscientists, image analysists, neurophysiologists, and 
geneticists are involved in the assessment of patients. As part of their 
assessment, participants undergo blood drawing (for APOE genotyping), clinical 
and cognitive evaluations as well as high-resolution MRI scanning (more details 
can be found in Frisoni et al., 2009 and Galluzzi et al., 2010). Here, we included 
the structural MRI of subjects between 47 to 73 years old, to match the age range 
of the UK Biobank dataset. The resulting group was composed of 319 subjects, 
including 215 HC, 67 patients with MCI (stage not known), and 37 patients with 
AD. Ethics approval for the ARWiBo study and all experimental protocols was 
provided by the local ethics committee and all participants signed an informed 
participation consent. All experiments and methods were carried out in 
accordance with the approved guidelines and regulations. 
The OASIS-1 dataset is the result of a collaborative effort of investigators 
from a single acquisition site supported by the National Institute on Aging (NIA), 
the Howard Hughes Medical Institute, the Biomedical Informatics Research 
Network (BIRN) and the Washington University Alzheimer’s Disease Research 
Center [Alzheimer’s Disease Research Center (ADRC)]. This collaborative effort 
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aimed to create a freely available MRI dataset for the wider scientific community. 
The original dataset consisted of a cross-sectional collection of subjects aged 18 
to 96. It included participants over the age of 60 who had received a clinical 
diagnosis of very mild to moderate AD (for more information, please see 
http://www.oasis-brains.org). In our analysis, we selected data collected from 
individuals who were between 47 to 73 years old, to match the age range of the 
UK Biobank dataset. The resulting group was composed of 78 subjects, including 
41 HC and 37 patients with AD. Ethics approval for the OASIS-1 study and all 
experimental protocols was provided by the local ethics committee and all 
participants signed an informed participation consent. All subjects participated in 
accordance with guidelines of the Washington University Human Studies 
Committee. All experiments and methods were carried out in accordance with the 
approved guidelines and regulations. 
The MIRIAD dataset was designed to establish the minimal interval over 
which it would be feasible to undertake clinical trials in AD using atrophy 
measured from longitudinal MRI as an outcome measure 21. Ethical approval for 
the MIRIAD study (and subsequently its release) was received from the local 
research ethics committee, and written consent obtained from all participants. All 
experiments and methods were carried out in accordance with the approved 
guidelines and regulations. Here, we included the structural MRI of subjects 
between 47 to 73 years old, to match the age range of the UK Biobank dataset. 
The resulting group was composed of 48 subjects, including 18 HC and 30 
patients with AD. 
In the present study, we used the UK Biobank set to train the autoencoders 
and the ADNI, AIBL, ARWiBo, OASIS-1, and MIRIAD datasets to assess the 
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normative model performance on data from patients with MCI and AD. To perform 
comparisons between HC and patient groups, we ensured that there were no 
significant statistical differences regarding age and sex in all three clinical 
datasets. We assessed each dataset independently using the ANOVA test to 
verify any differences in age and the Chi-square test of homogeneity to 
investigate differences in the sex ratios between groups (Table 1 and Table 2). 
Table 1 - Demographic information for the subjects from the UK Biobank dataset, the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) dataset, and the Australian Imaging Biomarkers and 
Lifestyle Study of Ageing (AIBL) dataset. We used ANOVA test and the chi‐square test of 
homogeneity to test for significant differences in age and sex between healthy controls and 
patients. Abbreviations: HC = healthy control; EMCI = early mild cognitive impairment; LMCI = 



























Age, y      .87    .28 
Mean ± SD 61.6±7.0 66.6±3.7 66.4±4.2 66.2±5.1 66.6±5.4  68.2±3.2 68.2±3.6 67.3±5.2  
Range [47, 73] [56, 72] [56, 73] [56, 73] [56, 73]  [60, 73] [56, 73] [55, 73]  
           
Sex, n (%)      .25    .15 
Men 5180 (47) 90 (42) 72 (45) 40 (49) 36 (56)  113 (43) 19 (41) 17 (45)  
Women 5854 (53) 122 (58) 87 (55) 42 (51) 28 (44)  149 (57) 27 (59) 21 (55)  
 
Table 2 - Demographic information for the subjects from the Alzheimer’s Disease Repository 
Without Borders (ARWiBo) dataset, the Open Access Series of Imaging Studies: Cross-Sectional 
(OASIS-1) dataset, and the Minimal Interval Resonance Imaging in Alzheimer's Disease 
(MIRIAD) dataset. We used ANOVA test and the chi‐square test of homogeneity to test for 
significant differences in age and sex between healthy controls and patients. Abbreviations: HC 



























Age, y    .16   .07   .71 
Mean ± SD 65.1±4.4 66.4±5.7 65.1±6.0  68.2±3.8 69.7±3.1  66.7±4.1 66.2±4.6  
Range [57, 73] [47, 73] [50, 73]  [61, 73] [62, 73]  [59, 73] [56, 73]  
           
Sex, n (%)    .70   .30   .76 
Men 86 (40) 23 (34) 14 (38)  11 (27) 14 (38)  7 (39) 13 (43)  





2.2. MRI Processing 
We used the FreeSurfer software (version 6.0) to estimate the brain 
regions’ volumes from the T1 weighted images. This estimation was performed 
using the “recon-all” command (see Fischl, 2012; Fischl et al., 2002, for more 
information). During this processing, the cortical surface of each hemisphere was 
parcellated according to the Desikan-Killiany atlas 29 and anatomical volumetric 
measures were obtained via a whole-brain segmentation procedure (Aseg atlas) 
28. The final data included the cortical volume for each of the 68 cortical 
subregions (34 per hemisphere) and the volume of 33 neuroanatomical 
structures, totalling 101 subregions/structures (the complete list is presented in 
the supplementary materials). 
 
2.3. Normative model 
In this paper, we developed the normative model using the adversarial 
autoencoder (AAE; Figure 1) 30,31. As an autoencoder, this neural network has an 
encoder and a decoder. The function of the encoder is to take in an input x and 
map it into a latent encoding space, creating a latent code h. Then, the goal of 
the decoder is to reconstruct the input data based on the latent code. The AAE is 
a blend of this autoencoder framework with adversarial training, which is used in 
generative adversarial networks modelling 32. This autoencoder uses the 
adversarial training to shape the distribution of the latent code to look similar to a 
predefined prior distribution. The AAE achieves this desired distribution by 
incorporating a discriminator network into its structure. In this scheme, the 
discriminator receives two types of inputs: random numbers sampled from the 
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desired prior distribution, and the latent code. During the training process, the 
discriminator will make predictions regarding whether its input data was sampled 
from the prior distribution or the latent code. The adversarial training forces the 
encoder to produce a latent code space that can fool the discriminator into 




Figure 1 – Structure of the normative model based on adversarial autoencoders. In this 
configuration, the subject data is inputted into the encoder and then mapped to the latent code. 
This latent code is fed to the decoder with the demographic data, and then the decoder generates 
a reconstruction of the original data. During the training of the model, the discriminator predicts if 
its input data came from the latent code or if it was randomly sampled from the chosen prior 
distribution (e.g. Gaussian distribution). Based on these predictions, the adversarial autoencoder 
forces the encoder to produce a latent code similar to the prior distribution selected. Since the 
model is trained on healthy controls data, it is expected that it can reconstruct similar data 
relatively well, yielding a small reconstruction error. However, the model is expected to generate 




In this study, we trained the AAE to codify and reconstruct the data of HC 
subjects. The main idea of this normative approach is that, since the AAE only 
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learns how to reconstruct images from HC individuals, it will be less precise at 
mapping images from patients, which differ due to the pathological mechanisms 
of the disorder. As a result, the difference between the reconstructed data and 
the original data will be larger in patients than HC individuals. 
Regarding our model architecture, we used an encoder with two hidden 
layers with 100 neurons, and a latent code with a size of 20 neurons. The decoder 
and the discriminator had a similar structure (two hidden layers with 100 
neurons). All hidden layers had a leaky ReLU non-linearity 33. The latent code 
and the decoder’s output layer had a linear activation function.  
 
2.4. Normative model training 
To train the autoencoder, first, we performed the pre-processing of the 
brain features. This involved estimating the relative brain region volumes for each 
subject by dividing the original brain region volumes by the total intracranial 
volume. Then, we normalised the relative brain region volumes across all the 
participants in the training set. In this step, we performed a normalisation robust 
to outliers by subtracting the median value of the relative brain region volume and 
then scaling the data according to its interquartile range. Centering and scaling 
was done independently for each brain region. The same relevant statistics 
(median and interquartile range) were later used to normalise the data from the 
clinical datasets before feeding them to the model. 
In our analyses, we used a conditioned AAE 30. This type of autoencoder 
allows us to influence the model’s reconstruction using the demographic 
variables, i.e. age and sex. To input these variables into the model, we 
transformed age and sex into one-hot encoding vectors. After this transformation, 
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each subject has an age vector with 27 positions, where each position 
corresponds to a year within the range of 47-73 years. In this vector, all positions 
have value zero except the one that indicates the subject’s age which has a value 
equal to 1. The subject’s sex was represented in a one-hot encoded vector with 
two positions, one for male and one for female. The AAE’s decoder used these 
vectors together with the latent code to reconstruct the brain data. This 
architecture forces the network to disentangle the label information from the latent 
code 30. 
With the features pre-processed and the conditioning data prepared, we 
trained the autoencoder to minimise the mean squared value of its reconstruction 
error using Adam optimizer 34 for 200 epochs. A minibatch approach was used in 
this gradient descent-based optimizer, with a batch size of 256. The model was 
trained with a cyclical learning rate 35, which allows convergence of the training 
with fewer epochs. We started using a base learning rate with a value of 0.0001 
and a maximum learning rate value of 0.005, chosen using the “LR Range Test” 
36. The learning rate cycle had a basic triangular shape with an amplitude 
decaying (gamma = 0.98). 
In this study, we accessed the robustness of the autoencoder approach by 
training it with different simulated sets using the bootstrapping as the resampling 
method. We created 1,000 bootstrapped sets (each one with n = 11,032) by 
sampling with replacement from the UK Biobank. These bootstrapped sets were 
used to train the AAE. With this resampling method, we calculated: the value of 
the mean deviation (section 2.5) for each group from the ADNI, AIBL, ARWiBo, 
OASIS-1, and MIRIAD datasets, the discriminative performance of the normative 
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approach (section 2.5), and the deviation from normality of each brain region 
(section 2.6). 
 
2.5. Analysis of the observed deviations 
Similar to Pinaya et al. 5, we processed the data of each subject using the 
AAE, and we calculated the mean squared error between the reconstruction and 








        (𝐸𝑞. 1) 
where 𝑥𝑖 is the normalised value of the brain region 𝑖, ?̂?𝑖 is the autoencoder 
reconstructed value of the brain region 𝑖, and 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑒𝑔𝑖𝑜𝑛𝑠 is the number 
of cortical regions and neuroanatomical structures used (i.e. 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑒𝑔𝑖𝑜𝑛𝑠 
= 101).  
In each iteration of the bootstrap method, we used the trained autoencoder 
to obtain the deviation metric of the subjects from the ADNI, AIBL, ARWiBo, 
OASIS-1, and MIRIAD datasets. Then, we calculated the difference between the 
mean deviation scores of each pair of groups. We identified a significant 
difference between groups if the confidence interval (95% of confidence) of this 
difference did not include the zero. Besides, we used the subjects’ deviations to 
obtain the discriminative performance of the autoencoder approach, measured 
by the area under the receiver operating characteristic curve (AUC). 
 
2.6. Brain regions deviations 
The autoencoder approach can quantify how much each brain region 
deviated from normality and contributed to the observed deviation. These values 
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were obtained by measuring the difference between the inputted value and its 
reconstruction. In our study, we quantified the deviation for each subject from the 
ADNI, AIBL, ARWiBo, OASIS-1, and MIRIAD datasets. Then, in each iteration of 
the bootstrap method, we calculated the effect size of each brain region deviation 
– using Cliff’s delta 37 value - between the HC group and each patient group. Here 
we used Cliff’s delta - a non-parametric effect size measure – because the 
observed deviation presents a gamma distribution. 
2.7. Comparison against traditional machine learning classification 
A further aim of the present study was to compare the performance of our 
normative model against a traditional classification approach. To measure the 
performance of the classifiers, we calculated the AUC using the .632+ bootstrap 
method 38 with 1,000 iterations. Each clinical dataset (ADNI, AIBL, ARWiBo, 
OASIS-1, and MIRIAD) was analysed independently using the HC and patient 
groups to train the classifiers. Besides, the analysis was performed as multiple 
binary classifications between HC and each clinical group (e.g. HC versus LMCI). 
In each iteration, first, we created the bootstrapped set by sampling the 
original data (from ADNI, AIBL, ARWiBo, OASIS-1, and MIRIAD datasets) with 
replacement. This bootstrapped set had the same size as the original dataset (for 
example, when analysing the ADNI dataset to classify healthy controls and 
patients with Alzheimer’s disease, the bootstrapped set had 212+64=276 
subjects), and it contained repeated subjects (due to replacement). For each 
iteration, the subjects not included in the bootstrapped set were used as the out-
of-bag set (i.e. test set). 
Next, we obtained the relative brain region volumes of each subject by 
dividing the original volume by the total intracranial volume. Then, we normalised 
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the values of the relative brain volumes across the subjects. In this normalisation 
step, we removed the median value of the brain regions and scaled the data 
according to the interquartile range. Centering and scaling was done 
independently for each brain region. The same relevant statistics (median and 
interquartile range) were later used to normalise the out-of-bag set. 
To perform the classification analysis, we used a relevance vector 
machine (RVM) 39 with a linear kernel. The RVM is a Bayesian treatment of 
identical functional form to the Support Vector Machines (SVM) 40. One 
advantage of the RVM form over the SVM is that it is not necessary to estimate 
the error/margin trade-off parameter ‘C’. After we trained the RVM on the 
bootstrapped set, we used the model to obtain the predicted probability of a 
subject belonging to the patient class. Using these probabilities, we calculated 
two AUC values, one for the bootstrapped set (called “resubstitution” metric) and 
one for the test set (called “out-of-bag” metric). By using the .632+ bootstrap 
method, we minimised the optimistic and pessimistic bias of the estimate and 




∑(𝜔 ∗ 𝐴𝑈𝐶𝑜𝑢𝑡−𝑜𝑓−𝑏𝑎𝑔,𝑖 + (1 − 𝜔) ∗ 𝐴𝑈𝐶𝑟𝑒𝑠𝑢𝑏𝑠𝑡𝑖𝑡𝑢𝑡𝑖𝑜𝑛,𝑖)
𝑏
𝑖=1
 (Eq. 2) 
where b was the number of iterations and the weight ω was defined considering 
the relative overfitting rate (full description in Efron and Tibshirani, 1997). To 
obtain the confidence interval (CI; 95% of confidence), we used the percentile 
method 41. Next, we compared these confidence intervals with the AUC obtained 
during the normative approach. 
Finally, we compared the generalization of the classifiers with the results 
of the autoencoders. In this analysis, we used each trained classifier to predict 
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the group of the subjects from the other clinical datasets. In order to verify if the 
performance in the independent datasets was significantly different from the 
normative approach, we calculated the difference between the AUCs of this 
generalization analysis and the AUCs of the autoencoders. With the 1,000 
measures of the difference, we calculated its confidence interval (95% 
confidence) to verify if this difference is different from zero.  
 
2.8. Experiments 
We conducted our experiments in Python 3 using the Tensorflow 2.0 
library (https://www.tensorflow.org/) and the sklearn_rvm library 
(https://github.com/Mind-the-Pineapple/sklearn-rvm) developed by Baecker et al. 
42. We have made publicly available the codes and trained models used in this 
study at https://github.com/Warvito/Normative-modelling-using-deep-
autoencoders. A Google’s Colaboratory notebook that calculates the deviations 
scores of new data is available at 
https://colab.research.google.com/github/Warvito/Normative-modelling-using-




3.1. Comparison of deviation values for healthy controls and patients 
Figure 2 shows the mean value of the observed deviation for each group. 
For the ADNI dataset, we found a mean value of 0.28 ([0.27, 0.32]; 95% CI) for 
HC; 0.29 ([0.28, 0.35]; 95% CI) for EMCI; 0.32 ([0.30, 0.38]; 95% CI) for LMCI; 
0.37 ([0.34, 0.47]; 95% CI) for AD. For the AIBL dataset, we found a mean value 
of 0.30 ([0.28, 0.33]; 95% CI) for HC; 0.36 ([0.34, 0.42]; 95% CI) for MCI; and 
0.40 ([0.36, 0.50]; 95% CI) for AD. For the ARWiBo dataset, we found a mean 
value of 0.32 ([0.30, 0.38]; 95% CI) for HC; 0.37 ([0.34, 0.47]; 95% CI) for MCI; 
and 0.46 ([0.40, 0.62]; 95% CI) for AD. For the OASIS-1 dataset, we found a 
mean value of 0.41 ([0.39, 0.46]; 95% CI) for HC and 0.65 ([0.58, 0.79]; 95% CI) 
for AD. For the MIRIAD dataset, we found a mean value of 0.26 ([0.24, 0.30]; 





Figure 2 – Mean value of the observed deviation calculated by the autoencoder for each group. 
The square marker indicates the mean value and the horizontal bars indicates the 95% 
confidence interval calculated using the percentile method on the bootstrap analysis. 
Abbreviations: AD = Alzheimer’s disease; EMCI = early mild cognitive impairment; LMCI = late 
mild cognitive impairment; MCI = mild cognitive impairment; HC = healthy controls; ADNI = 
Alzheimer’s Disease Neuroimaging Initiative; AIBL = Australian Imaging Biomarkers and Lifestyle 
Study of Ageing; ARWiBo = Alzheimer's Disease Repository Without Borders; OASIS-1 = Open 
Access Series of Imaging Studies: Cross-Sectional; MIRIAD = Minimal Interval Resonance 
Imaging in Alzheimer's Disease. 
 
 
When we examined the confidence intervals of the observed deviations, 
we found that the five independent datasets presented mean deviation scores 
significantly different between groups, with the exception of the comparison 
between HC and EMCI in the ADNI dataset (difference range [-0.03, 0.00]) and 
the comparison between MCI and AD in the AIBL dataset (difference range [-




3.2. Normative model performance in discriminative tasks 
We examined if the observed deviations could be used to predict if a 
person belonged to the patient or HC group (Figure 3) using ROC curves. This 
revealed that the generated deviation values reflected the severity of the disease. 
Specifically, based on the AUC, it was possible to discriminate patients with AD 
vs HC better than patients with MCI vs HC, and to discriminate patients with LMCI 
vs HC better than patients with EMCI vs HC. 
 
 
Figure 3 – Discriminative performance of the normative approach. The solid line indicates the 
mean receiver operating characteristic curve across the bootstrap iterations with the shaded area 
indicating the 95% confidence interval calculated using the percentile method on the bootstrap 
analysis. The dashed line indicates the chance level. Abbreviations: AD = Alzheimer’s disease; 
AUC-ROC = area under the receiver operating characteristic curve; EMCI = early mild cognitive 
impairment; LMCI = late mild cognitive impairment; MCI = mild cognitive impairment; HC = healthy 
controls; ADNI = Alzheimer’s Disease Neuroimaging Initiative; AIBL = Australian Imaging 
Biomarkers and Lifestyle Study of Ageing; ARWiBo = Alzheimer's Disease Repository Without 
Borders; OASIS-1 = Open Access Series of Imaging Studies: Cross-Sectional; MIRIAD = Minimal 






3.3. Brain regions deviations 
Figure 4 present the Cliff’s delta of each brain region when comparing its 
deviation in the HC group against the deviation in the patient groups. Only the 
regions with effect sizes significantly different from zero are shown (complete list 
presented in the supplementary materials). Among the regions showing 
significant deviation in patients with AD, we found the lateral ventricles, temporal 
horns, hippocampus, entorhinal cortex, parahippocampal cortex, and amygdala. 
A number of these regions also showed a high deviation in patients with MCI, 
including the lateral ventricles and hippocampus. Finally, we also noted that effect 
sizes were smaller for the regions identified in patients with MCI relative to those 





Figure 4 – Brain regions deviations. The square marker indicates the mean effect size (Cliff’s 
delta) between the healthy control group and the respective patient groups. The horizontal bars 
indicate the 95% confidence interval calculated using the percentile method on the bootstrap 
analysis. Only the regions with a mean effect size significantly different from zero are presented. 
Abbreviations: AD = Alzheimer’s disease; AUC-ROC = area under the receiver operating 
characteristic curve; EMCI = early mild cognitive impairment; LMCI = late mild cognitive 
impairment; MCI = mild cognitive impairment; HC = healthy controls; ADNI = Alzheimer’s Disease 
Neuroimaging Initiative; AIBL = Australian Imaging Biomarkers and Lifestyle Study of Ageing; 
ARWiBo = Alzheimer's Disease Repository Without Borders; OASIS-1 = Open Access Series of 






3.4. Traditional machine learning classification 
Using the RVM, we verified the performance of a traditional classifier when 
performing binary classification between HC and patients. For the ADNI dataset, 
we obtained an AUC = 0.69 ([0.58, 0.77]; 95% CI) when analysing patients with 
EMCI, an AUC = 0.76 ([0.64, 0.84]; 95% CI) when analysing patients with LMCI, 
and an AUC = 0.93 ([0.87, 0.97]; 95% CI) when analysing patients with AD. For 
the AIBL dataset, an AUC = 0.37 ([0.00, 0.78]; 95% CI) when analysing subjects 
with MCI, and we obtained an AUC = 0.93 ([0.86, 0.93]; 95% CI) when analysing 
patients with AD. Note, that the AUC for the AIBL dataset when analysing MCI 
had a wide interval. This interval was exacerbated due to the presence of 
overfitting and the .632+ bootstrap method compensatory effect that reduce the 
effect of bias caused by this overfitting. For the ARWiBo dataset, we obtained an 
AUC = 0.68 ([0.52, 0.78]; 95% CI) when analysing subjects with MCI, and an AUC 
= 0.94 ([0.87, 0.98]; 95% CI) when analysing patients with AD. For the OASIS-1 
dataset, we obtained an AUC = 0.86 ([0.69, 0.96]; 95% CI) when analysing 
patients with AD. For the MIRIAD dataset, we obtained an AUC = 0.86 ([0.70, 
0.96]; 95% CI) when analysing patients with AD. 
To identify significant differences between the performance of the 
normative models and traditional classifiers, we calculated the confidence interval 
(95% of confidence) of the difference in AUC between the two methods. The 
traditional classifiers were superior to the normative models when predicting the 
difference between the groups in the ADNI dataset and the difference between 
HC and AD in the AIBL dataset; in contrast the performance of the two 
approaches was comparable for all other comparisons (more details can be found 
in the supplementary materials).  
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Finally, we examined how a classifier trained on a certain dataset would 
perform when applied to other datasets (i.e. cross-cohort generalizability). The 
results of this examination are presented in Table 3 and Table 4. When predicting 
AD, the classifiers had a higher mean performance than the normative approach 
in most cases (except when the model was trained on MIRIAD dataset and 
evaluated on ARWiBo dataset). However, the difference was not significantly 
different in almost half of the cases. When predicting MCI, the classifiers 
presented a lower mean performance in all cases, but the difference was not 
significantly different. 
 
Table 3 – Generalization performance of the classifiers for the classification between HC and 
patients with Alzheimer’s disease. In this table, the rows indicate the dataset where the classifier 
is trained and the columns indicate the dataset where the performance was tested. The area 
under the receiver operating characteristic curve is shown with the upper and lower bound of its 
95% confidence interval. Performance significantly different from the normative approach 
calculated using the confidence interval of the difference between the approach across the 
bootstrap scheme is indicated by “*”. 
 
 ADNI AIBL ARWiBo OASIS-1 MIRIAD 
ADNI - 0.89 [0.93, 0.83] * 0.88 [0.81, 0.93] 0.84 [0.76, 0.90] * 0.98 [0.95, 1.00] 
AIBL 0.88 [0.82, 0.93] * - 0.89 [0.93, 0.83] * 0.86 [0.80, 0.91] * 0.98 [0.94, 1.00] 
ARWiBo 0.88 [0.81, 0.92] * 0.88 [0.83, 0.92] * - 0.80 [0.72, 0.86] 0.96 [0.91, 0.99] 
OASIS-1 0.90 [0.84, 0.93] * 0.89 [0.83, 0.93] * 0.86 [0.77, 0.92] - 0.96 [0.91, 1.00] 
MIRIAD 0.89 [0.83, 0.93] * 0.87 [0.80, 0.91] * 0.82 [0.73, 0.91] 0.83 [0.74, 0.89] - 
 
 
Table 4 - Generalization performance of the classifiers for the classification between HC and 
patients with mild cognitive impairment. In this table, the rows indicate the dataset where the 
classifier is trained and the columns indicate the dataset where the performance was measured. 
The area under the receiver operating characteristic curve is shown with the upper and lower 
bound of its 95% confidence interval. No case had a performance significantly different from the 
normative approach calculated using the confidence interval of the difference between the 
approach across the bootstrap scheme. 
 
 AIBL ARWiBo 
AIBL - 0.61 [0.54, 0.67] 






In this study, we evaluated the performance of the normative modelling 
approach based on deep autoencoders on data from patients with MCI and AD. 
Consistent with our first hypothesis, we found that the approach was effective in 
generating deviation values that reflect the severity of the disease, with patients 
with AD showing higher deviations than patients with MCI, and patients with LMCI 
showing larger deviations than patients with EMCI. We also measured how much 
each brain region deviated from normality and contributed to the observed 
deviation. Here, we found that regions from the ventricular system and medial 
temporal lobe were among those making the greatest significant contribution to 
deviation, consistent with our second hypothesis. Finally, we compared the 
performance of the normative approach versus a traditional classification 
approach. Although a higher performance was found for traditional classifiers in 
most cases, the difference was not statistically significant in the majority of cases. 
We have replicated previous findings that the autoencoder is capable of 
detecting neuroanatomical deviation in individuals with brain disorders 5. In 
particular, in each of our five independent datasets, the normative model was 
able to assign higher values to patients with AD than healthy controls. This 
pattern was expected since the disorder is associated with profound alterations 
in the brain morphometry which were not present in the training set 13,14. In 
addition, we have expanded these findings by demonstrating for the first time that 
autoencoders are capable of discriminating between different stages of the 
disease progress (i.e. EMCI versus LMCI versus AD). In particular, we observed 
that the MCI group presented intermediary deviation values in three independent 
datasets (ADNI, AIBL and ARWiBo). These values were also expected since the 
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MCI is considered as a transitory stage between HC and AD 43, and usually 
present less brain atrophy compared to AD 44. In addition, within the ADNI 
dataset, the MCI subjects were divided into two categories, EMCI and LMCI. 
Although individuals in both stages meet the conventional criteria for MCI, EMCI 
is associated with less pronounced symptoms thought to reflect an earlier point 
in the clinical spectrum than LMCI. In our analyses, we found that the patients 
with LMCI had a significantly (i.e. the confidence interval of the difference 
between the group do not overlap zero) larger deviation than patients with EMCI 
providing further confirmation that that deep autoencoders are capable of 
discriminating between different stages of the disease course.  
With the autoencoder based approach, it was possible to identify the brain 
regions with the highest deviations from the expected normative values. 
Consistent with our second hypothesis, the AD group showed high levels of 
deviation in structures that are part of the ventricular system (such as the lateral 
ventricles, temporal horns, and 3rd ventricle) and in the medial temporal cortex, 
including the hippocampus, entorhinal cortex, parahippocampal cortex, and 
amygdala. Progressive ventricular expansion is one of the most reliable 
morphological changes in dementia patients, reflecting the increasing atrophy of 
the brain 45. Likewise, medial temporal cortex atrophy is among the most 
consistent findings in neuroimaging studies of AD 13,46 and an established marker 
of AD 47. While deviations in the MCI group had a smaller sizes than those in the 
AD group, there was a high degree of overlap in the hippocampus, 
parahippocampal cortex and several temporoparietal regions, consistent with 
previous neuroimaging studies of MCI 48–51.  The smaller effect size in MCI might 
be explained by two (not mutually-exclusive) factors: i) earlier stage in the AD 
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course, hence milder atrophy, ii) heterogeneity of the MCI construct. Since MCI 
patients were not selected based on AD biomarkers (i.e., presence of beta-
amyloid and tau protein in the cerebrospinal fluid) 52, this group will likely include 
a mixture of AD and non-AD cases, hence the milder/diluted effect. 
Finally, we compared the performance of our normative approach with 
traditional classifiers. The performance of the classifiers was measured in two 
schemes, on data from the same dataset where the model was trained and on 
data from independent clinical datasets (generalization performance). Although 
the traditional classifiers had a better mean performance in most cases, the 
differences between the two approaches were not statistically significant in most 
of the cases, especially when predicting the subjects from the ARWiBo, OASIS-
1 and MIRIAD datasets. This similarity was more evident during the prediction of 
the patients with MCI (with exception the ADNI dataset). 
Although we evaluated our method using a range of different datasets, we 
did not assess the impact of MRI scanners and acquisition parameters. Recent 
studies have showed that these variables can have a measurable impact on the 
performance of machine learning models, highlighting the importance of inter-
scanner harmonisation 53,54. In particular, MRI scanners and acquisition 
parameters have been shown to influence the results not only in traditional 
machine learning classification but also normative modelling 55. For this reason, 
further studies need to be performed to analyse the influence of inter-scanner 
harmonisation, which can be implemented using tools such as Neuroharmony 54 
or Combat 56, on the performance of autoencoder based methods.  
Different from a case-control context, the normative approach does not 
need to be trained in a dataset with reasonable balancing between HC and 
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patient groups. It is trained using only healthy controls, which enables the use of 
large cohorts of HC participants 1,9, such as UK Biobank and Human Connectome 
Project 57. Our approach is not linked with any labels during training; this enables 
its application to an array of clinical tasks (including diagnosis, prognosis, 
treatment selection and mechanistic inference) for any brain disorder without the 
necessity of re-training or fine-tuning. Finally, since our approach involves 
anomaly detection, it can also work cooperatively with conventional discriminative 
models to identify and mitigate circumstances where supervised methods could 
catastrophic fail due to a test example very distinct from the training set (“out-of-
distribution” examples). In order to promote open science, we have made all 
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2. Univariate analysis – ADNI dataset– HC vs EMCI 
Supplementary Table 1 - Statistical significance measured by the Mann-Whitney U test and effect 
size measured by Cliff’s delta absolute value based on the comparison of the reconstruction error 
for each brain region between the HC and the EMCI groups from the ADNI dataset. The regions 
with p-value <= 0.05 are highlighted in bold. 
Regions Effect size p-value Regions Effect size p-value 
Left-Lateral-Ventricle -0.045 0.230 lh_parstriangularis_volume 0.130 0.016 
Left-Inf-Lat-Vent -0.112 0.033 lh_pericalcarine_volume 0.046 0.226 
Left-Cerebellum-White-Matter -0.039 0.260 lh_postcentral_volume 0.077 0.101 
Left-Cerebellum-Cortex 0.094 0.060 lh_posteriorcingulate_volume 0.140 0.010 
Left-Thalamus-Proper 0.209 >0.001 lh_precentral_volume 0.060 0.160 
Left-Caudate 0.062 0.153 lh_precuneus_volume 0.085 0.081 
Left-Putamen 0.025 0.339 lh_rostralanteriorcingulate_volume 0.095 0.059 
Left-Pallidum -0.019 0.380 lh_rostralmiddlefrontal_volume 0.124 0.021 
3rd-Ventricle -0.021 0.365 lh_superiorfrontal_volume 0.148 0.007 
4th-Ventricle 0.153 0.006 lh_superiorparietal_volume 0.047 0.220 
Brain-Stem 0.090 0.069 lh_superiortemporal_volume 0.139 0.011 
Left-Hippocampus 0.085 0.082 lh_supramarginal_volume 0.034 0.289 
Left-Amygdala 0.079 0.097 lh_frontalpole_volume -0.071 0.121 
CSF -0.108 0.038 lh_temporalpole_volume 0.143 0.009 
Left-Accumbens-area 0.008 0.447 lh_transversetemporal_volume 0.033 0.295 
Left-VentralDC 0.038 0.265 lh_insula_volume 0.189 0.001 
Right-Lateral-Ventricle -0.050 0.205 rh_bankssts_volume 0.005 0.466 
Right-Inf-Lat-Vent -0.103 0.046 rh_caudalanteriorcingulate_volume 0.006 0.460 
Right-Cerebellum-White-Matter -0.065 0.142 rh_caudalmiddlefrontal_volume 0.132 0.015 
Right-Cerebellum-Cortex 0.112 0.033 rh_cuneus_volume -0.031 0.306 
Right-Thalamus-Proper 0.199 0.001 rh_entorhinal_volume 0.010 0.437 
Right-Caudate 0.072 0.116 rh_fusiform_volume 0.062 0.153 
Right-Putamen 0.010 0.437 rh_inferiorparietal_volume 0.065 0.141 
Right-Pallidum -0.016 0.398 rh_inferiortemporal_volume 0.024 0.345 
Right-Hippocampus 0.123 0.022 rh_isthmuscingulate_volume 0.068 0.130 
Right-Amygdala 0.008 0.448 rh_lateraloccipital_volume -0.012 0.420 
Right-Accumbens-area -0.107 0.039 rh_lateralorbitofrontal_volume 0.091 0.067 
Right-VentralDC 0.027 0.328 rh_lingual_volume -0.050 0.207 
CC_Posterior -0.035 0.284 rh_medialorbitofrontal_volume 0.156 0.005 
CC_Mid_Posterior 0.029 0.318 rh_middletemporal_volume 0.100 0.050 
CC_Central 0.103 0.045 rh_parahippocampal_volume 0.029 0.315 
CC_Mid_Anterior 0.031 0.304 rh_paracentral_volume 0.113 0.032 
CC_Anterior -0.033 0.292 rh_parsopercularis_volume 0.109 0.036 
lh_bankssts_volume 0.118 0.026 rh_parsorbitalis_volume 0.025 0.338 
lh_caudalanteriorcingulate_volume 0.065 0.140 rh_parstriangularis_volume 0.075 0.109 
lh_caudalmiddlefrontal_volume 0.031 0.306 rh_pericalcarine_volume 0.078 0.099 
lh_cuneus_volume -0.041 0.248 rh_postcentral_volume 0.101 0.048 
lh_entorhinal_volume -0.092 0.065 rh_posteriorcingulate_volume 0.056 0.179 
lh_fusiform_volume 0.052 0.195 rh_precentral_volume 0.105 0.041 
lh_inferiorparietal_volume 0.100 0.049 rh_precuneus_volume 0.042 0.242 
lh_inferiortemporal_volume 0.092 0.064 rh_rostralanteriorcingulate_volume 0.112 0.033 
lh_isthmuscingulate_volume -0.048 0.213 rh_rostralmiddlefrontal_volume 0.084 0.083 
lh_lateraloccipital_volume -0.002 0.484 rh_superiorfrontal_volume 0.114 0.030 
lh_lateralorbitofrontal_volume 0.077 0.101 rh_superiorparietal_volume 0.030 0.308 
lh_lingual_volume 0.007 0.457 rh_superiortemporal_volume 0.221 0.000 
lh_medialorbitofrontal_volume 0.232 0.000 rh_supramarginal_volume 0.083 0.084 
lh_middletemporal_volume 0.109 0.037 rh_frontalpole_volume -0.104 0.043 
lh_parahippocampal_volume -0.014 0.406 rh_temporalpole_volume 0.116 0.028 
lh_paracentral_volume 0.126 0.019 rh_transversetemporal_volume 0.139 0.011 
lh_parsopercularis_volume 0.134 0.014 rh_insula_volume 0.172 0.002 
lh_parsorbitalis_volume -0.012 0.424    
  
3. Univariate analysis – ADNI dataset – HC vs LMCI 
Supplementary Table 2 - Statistical significance measured by the Mann-Whitney U test and effect 
size measured by Cliff’s delta absolute value based on the comparison of the reconstruction error 
for each brain region between the HC and the LMCI groups from the ADNI dataset. The regions 
with p-value <= 0.05 are highlighted in bold. 
Regions Effect size p-value Regions Effect size p-value 
Left-Lateral-Ventricle -0.106 0.080 lh_parstriangularis_volume 0.232 0.001 
Left-Inf-Lat-Vent -0.299 >0.001 lh_pericalcarine_volume 0.065 0.193 
Left-Cerebellum-White-Matter -0.054 0.238 lh_postcentral_volume 0.191 0.006 
Left-Cerebellum-Cortex 0.127 0.045 lh_posteriorcingulate_volume 0.132 0.040 
Left-Thalamus-Proper 0.240 0.001 lh_precentral_volume 0.147 0.026 
Left-Caudate 0.098 0.096 lh_precuneus_volume 0.246 0.001 
Left-Putamen 0.098 0.096 lh_rostralanteriorcingulate_volume 0.113 0.066 
Left-Pallidum 0.016 0.415 lh_rostralmiddlefrontal_volume 0.239 0.001 
3rd-Ventricle -0.161 0.016 lh_superiorfrontal_volume 0.287 >0.001 
4th-Ventricle 0.039 0.301 lh_superiorparietal_volume 0.120 0.055 
Brain-Stem 0.068 0.183 lh_superiortemporal_volume 0.298 >0.001 
Left-Hippocampus 0.366 >0.001 lh_supramarginal_volume 0.231 0.001 
Left-Amygdala 0.278 >0.001 lh_frontalpole_volume 0.123 0.051 
CSF -0.245 0.001 lh_temporalpole_volume 0.142 0.029 
Left-Accumbens-area 0.222 0.002 lh_transversetemporal_volume 0.086 0.126 
Left-VentralDC 0.112 0.068 lh_insula_volume 0.254 >0.001 
Right-Lateral-Ventricle -0.106 0.079 rh_bankssts_volume 0.227 0.001 
Right-Inf-Lat-Vent -0.258 >0.001 rh_caudalanteriorcingulate_volume 0.001 0.493 
Right-Cerebellum-White-Matter -0.108 0.076 rh_caudalmiddlefrontal_volume 0.142 0.029 
Right-Cerebellum-Cortex 0.118 0.058 rh_cuneus_volume 0.079 0.147 
Right-Thalamus-Proper 0.336 >0.001 rh_entorhinal_volume 0.214 0.002 
Right-Caudate 0.066 0.192 rh_fusiform_volume 0.198 0.004 
Right-Putamen 0.087 0.125 rh_inferiorparietal_volume 0.345 >0.001 
Right-Pallidum -0.044 0.280 rh_inferiortemporal_volume 0.267 >0.001 
Right-Hippocampus 0.382 >0.001 rh_isthmuscingulate_volume 0.106 0.080 
Right-Amygdala 0.157 0.018 rh_lateraloccipital_volume 0.173 0.011 
Right-Accumbens-area 0.026 0.363 rh_lateralorbitofrontal_volume 0.125 0.048 
Right-VentralDC 0.106 0.080 rh_lingual_volume 0.081 0.141 
CC_Posterior 0.013 0.429 rh_medialorbitofrontal_volume 0.189 0.006 
CC_Mid_Posterior -0.032 0.337 rh_middletemporal_volume 0.349 >0.001 
CC_Central 0.083 0.134 rh_parahippocampal_volume 0.178 0.009 
CC_Mid_Anterior 0.105 0.081 rh_paracentral_volume 0.167 0.013 
CC_Anterior 0.012 0.436 rh_parsopercularis_volume 0.126 0.047 
lh_bankssts_volume 0.335 >0.001 rh_parsorbitalis_volume 0.139 0.032 
lh_caudalanteriorcingulate_volume -0.092 0.110 rh_parstriangularis_volume 0.212 0.002 
lh_caudalmiddlefrontal_volume 0.240 0.001 rh_pericalcarine_volume 0.052 0.245 
lh_cuneus_volume 0.012 0.435 rh_postcentral_volume 0.089 0.120 
lh_entorhinal_volume 0.210 0.003 rh_posteriorcingulate_volume 0.265 >0.001 
lh_fusiform_volume 0.371 >0.001 rh_precentral_volume 0.034 0.327 
lh_inferiorparietal_volume 0.377 >0.001 rh_precuneus_volume 0.237 0.001 
lh_inferiortemporal_volume 0.227 0.001 rh_rostralanteriorcingulate_volume 0.057 0.226 
lh_isthmuscingulate_volume 0.130 0.043 rh_rostralmiddlefrontal_volume 0.271 >0.001 
lh_lateraloccipital_volume 0.122 0.053 rh_superiorfrontal_volume 0.249 >0.001 
lh_lateralorbitofrontal_volume 0.145 0.027 rh_superiorparietal_volume 0.241 0.001 
lh_lingual_volume 0.112 0.069 rh_superiortemporal_volume 0.334 >0.001 
lh_medialorbitofrontal_volume 0.197 0.004 rh_supramarginal_volume 0.230 0.001 
lh_middletemporal_volume 0.344 >0.001 rh_frontalpole_volume -0.029 0.352 
lh_parahippocampal_volume 0.167 0.013 rh_temporalpole_volume 0.089 0.118 
lh_paracentral_volume 0.125 0.048 rh_transversetemporal_volume 0.033 0.332 
lh_parsopercularis_volume 0.247 0.001 rh_insula_volume 0.204 0.003 
lh_parsorbitalis_volume 0.075 0.160    
 
  
4. Univariate analysis – ADNI dataset – HC vs AD 
Supplementary Table 3 - Statistical significance measured by the Mann-Whitney U test and effect 
size measured by Cliff’s delta absolute value based on the comparison of the reconstruction error 
for each brain region between the HC and the AD groups from the ADNI dataset. The regions 
with p-value <= 0.05 are highlighted in bold. 
Regions Effect size p-value Regions Effect size p-value 
Left-Lateral-Ventricle -0.552 >0.001 lh_parstriangularis_volume 0.420 >0.001 
Left-Inf-Lat-Vent -0.708 >0.001 lh_pericalcarine_volume 0.246 0.001 
Left-Cerebellum-White-Matter -0.040 0.316 lh_postcentral_volume 0.330 >0.001 
Left-Cerebellum-Cortex 0.103 0.106 lh_posteriorcingulate_volume 0.414 >0.001 
Left-Thalamus-Proper 0.488 >0.001 lh_precentral_volume 0.317 >0.001 
Left-Caudate 0.179 0.015 lh_precuneus_volume 0.640 >0.001 
Left-Putamen 0.378 >0.001 lh_rostralanteriorcingulate_volume 0.328 >0.001 
Left-Pallidum -0.052 0.264 lh_rostralmiddlefrontal_volume 0.581 >0.001 
3rd-Ventricle -0.542 >0.001 lh_superiorfrontal_volume 0.633 >0.001 
4th-Ventricle -0.075 0.181 lh_superiorparietal_volume 0.424 >0.001 
Brain-Stem 0.189 0.011 lh_superiortemporal_volume 0.676 >0.001 
Left-Hippocampus 0.748 >0.001 lh_supramarginal_volume 0.587 >0.001 
Left-Amygdala 0.768 >0.001 lh_frontalpole_volume 0.204 0.007 
CSF -0.528 >0.001 lh_temporalpole_volume 0.203 0.007 
Left-Accumbens-area 0.458 >0.001 lh_transversetemporal_volume 0.276 >0.001 
Left-VentralDC 0.277 >0.001 lh_insula_volume 0.401 >0.001 
Right-Lateral-Ventricle -0.533 >0.001 rh_bankssts_volume 0.554 >0.001 
Right-Inf-Lat-Vent -0.705 >0.001 rh_caudalanteriorcingulate_volume 0.082 0.160 
Right-Cerebellum-White-Matter -0.080 0.166 rh_caudalmiddlefrontal_volume 0.442 >0.001 
Right-Cerebellum-Cortex 0.153 0.032 rh_cuneus_volume 0.148 0.037 
Right-Thalamus-Proper 0.499 >0.001 rh_entorhinal_volume 0.430 >0.001 
Right-Caudate 0.136 0.049 rh_fusiform_volume 0.698 >0.001 
Right-Putamen 0.371 >0.001 rh_inferiorparietal_volume 0.618 >0.001 
Right-Pallidum 0.002 0.491 rh_inferiortemporal_volume 0.621 >0.001 
Right-Hippocampus 0.719 >0.001 rh_isthmuscingulate_volume 0.412 >0.001 
Right-Amygdala 0.685 >0.001 rh_lateraloccipital_volume 0.422 >0.001 
Right-Accumbens-area 0.349 >0.001 rh_lateralorbitofrontal_volume 0.422 >0.001 
Right-VentralDC 0.230 0.003 rh_lingual_volume 0.231 0.003 
CC_Posterior -0.026 0.376 rh_medialorbitofrontal_volume 0.415 >0.001 
CC_Mid_Posterior 0.177 0.016 rh_middletemporal_volume 0.697 >0.001 
CC_Central 0.383 >0.001 rh_parahippocampal_volume 0.416 >0.001 
CC_Mid_Anterior 0.306 >0.001 rh_paracentral_volume 0.264 0.001 
CC_Anterior 0.059 0.238 rh_parsopercularis_volume 0.310 >0.001 
lh_bankssts_volume 0.656 >0.001 rh_parsorbitalis_volume 0.349 >0.001 
lh_caudalanteriorcingulate_volume -0.035 0.337 rh_parstriangularis_volume 0.266 0.001 
lh_caudalmiddlefrontal_volume 0.487 >0.001 rh_pericalcarine_volume 0.211 0.005 
lh_cuneus_volume 0.200 0.008 rh_postcentral_volume 0.318 >0.001 
lh_entorhinal_volume 0.514 >0.001 rh_posteriorcingulate_volume 0.427 >0.001 
lh_fusiform_volume 0.621 >0.001 rh_precentral_volume 0.280 >0.001 
lh_inferiorparietal_volume 0.644 >0.001 rh_precuneus_volume 0.573 >0.001 
lh_inferiortemporal_volume 0.641 >0.001 rh_rostralanteriorcingulate_volume 0.143 0.041 
lh_isthmuscingulate_volume 0.446 >0.001 rh_rostralmiddlefrontal_volume 0.555 >0.001 
lh_lateraloccipital_volume 0.388 >0.001 rh_superiorfrontal_volume 0.450 >0.001 
lh_lateralorbitofrontal_volume 0.439 >0.001 rh_superiorparietal_volume 0.519 >0.001 
lh_lingual_volume 0.354 >0.001 rh_superiortemporal_volume 0.613 >0.001 
lh_medialorbitofrontal_volume 0.453 >0.001 rh_supramarginal_volume 0.572 >0.001 
lh_middletemporal_volume 0.686 >0.001 rh_frontalpole_volume 0.072 0.190 
lh_parahippocampal_volume 0.458 >0.001 rh_temporalpole_volume 0.297 >0.001 
lh_paracentral_volume 0.250 0.001 rh_transversetemporal_volume 0.230 0.003 
lh_parsopercularis_volume 0.382 >0.001 rh_insula_volume 0.468 >0.001 
lh_parsorbitalis_volume 0.271 0.001    
  
5. Univariate analysis – AIBL dataset – HC vs MCI 
Supplementary Table 4 - Statistical significance measured by the Mann-Whitney U test and effect 
size measured by Cliff’s delta absolute value based on the comparison of the reconstruction error 
for each brain region between the HC and the MCI groups from the AIBL dataset. The regions 
with p-value <= 0.05 are highlighted in bold. 
Regions Effect size p-value Regions Effect size p-value 
Left-Lateral-Ventricle -0.125 0.088 lh_parstriangularis_volume -0.008 0.466 
Left-Inf-Lat-Vent -0.273 0.002 lh_pericalcarine_volume 0.109 0.120 
Left-Cerebellum-White-Matter 0.128 0.084 lh_postcentral_volume 0.144 0.059 
Left-Cerebellum-Cortex 0.140 0.065 lh_posteriorcingulate_volume 0.075 0.210 
Left-Thalamus-Proper 0.104 0.132 lh_precentral_volume 0.067 0.236 
Left-Caudate 0.115 0.106 lh_precuneus_volume 0.294 0.001 
Left-Putamen -0.013 0.444 lh_rostralanteriorcingulate_volume 0.090 0.164 
Left-Pallidum -0.045 0.313 lh_rostralmiddlefrontal_volume 0.205 0.013 
3rd-Ventricle -0.234 0.006 lh_superiorfrontal_volume 0.236 0.005 
4th-Ventricle -0.037 0.343 lh_superiorparietal_volume 0.077 0.202 
Brain-Stem 0.005 0.480 lh_superiortemporal_volume 0.261 0.002 
Left-Hippocampus 0.299 0.001 lh_supramarginal_volume 0.105 0.129 
Left-Amygdala 0.218 0.009 lh_frontalpole_volume 0.116 0.106 
CSF -0.323 0.000 lh_temporalpole_volume 0.258 0.003 
Left-Accumbens-area -0.019 0.417 lh_transversetemporal_volume 0.038 0.341 
Left-VentralDC -0.017 0.427 lh_insula_volume 0.223 0.008 
Right-Lateral-Ventricle -0.167 0.035 rh_bankssts_volume 0.108 0.123 
Right-Inf-Lat-Vent -0.364 >0.001 rh_caudalanteriorcingulate_volume 0.000 0.500 
Right-Cerebellum-White-Matter 0.145 0.058 rh_caudalmiddlefrontal_volume 0.150 0.053 
Right-Cerebellum-Cortex 0.159 0.042 rh_cuneus_volume 0.108 0.122 
Right-Thalamus-Proper 0.165 0.037 rh_entorhinal_volume 0.150 0.052 
Right-Caudate 0.029 0.379 rh_fusiform_volume 0.243 0.004 
Right-Putamen -0.001 0.496 rh_inferiorparietal_volume 0.173 0.031 
Right-Pallidum 0.020 0.413 rh_inferiortemporal_volume 0.140 0.065 
Right-Hippocampus 0.311 >0.001 rh_isthmuscingulate_volume 0.260 0.003 
Right-Amygdala 0.210 0.012 rh_lateraloccipital_volume 0.129 0.082 
Right-Accumbens-area -0.025 0.392 rh_lateralorbitofrontal_volume 0.253 0.003 
Right-VentralDC -0.077 0.201 rh_lingual_volume 0.189 0.020 
CC_Posterior 0.008 0.467 rh_medialorbitofrontal_volume 0.115 0.106 
CC_Mid_Posterior 0.117 0.104 rh_middletemporal_volume 0.176 0.029 
CC_Central 0.048 0.302 rh_parahippocampal_volume 0.154 0.048 
CC_Mid_Anterior 0.118 0.101 rh_paracentral_volume 0.134 0.073 
CC_Anterior 0.062 0.250 rh_parsopercularis_volume 0.106 0.126 
lh_bankssts_volume 0.203 0.014 rh_parsorbitalis_volume 0.055 0.278 
lh_caudalanteriorcingulate_volume 0.030 0.374 rh_parstriangularis_volume 0.093 0.158 
lh_caudalmiddlefrontal_volume 0.189 0.021 rh_pericalcarine_volume 0.077 0.203 
lh_cuneus_volume 0.193 0.018 rh_postcentral_volume 0.173 0.031 
lh_entorhinal_volume 0.340 >0.001 rh_posteriorcingulate_volume 0.063 0.247 
lh_fusiform_volume 0.249 0.003 rh_precentral_volume 0.131 0.079 
lh_inferiorparietal_volume 0.089 0.168 rh_precuneus_volume 0.223 0.008 
lh_inferiortemporal_volume 0.143 0.061 rh_rostralanteriorcingulate_volume 0.177 0.028 
lh_isthmuscingulate_volume 0.136 0.071 rh_rostralmiddlefrontal_volume 0.091 0.162 
lh_lateraloccipital_volume 0.142 0.062 rh_superiorfrontal_volume 0.250 0.003 
lh_lateralorbitofrontal_volume 0.248 0.004 rh_superiorparietal_volume 0.241 0.005 
lh_lingual_volume 0.126 0.087 rh_superiortemporal_volume 0.239 0.005 
lh_medialorbitofrontal_volume 0.292 0.001 rh_supramarginal_volume 0.092 0.160 
lh_middletemporal_volume 0.120 0.097 rh_frontalpole_volume 0.081 0.189 
lh_parahippocampal_volume 0.095 0.151 rh_temporalpole_volume 0.188 0.021 
lh_paracentral_volume 0.101 0.138 rh_transversetemporal_volume 0.197 0.017 
lh_parsopercularis_volume 0.049 0.298 rh_insula_volume 0.252 0.003 
lh_parsorbitalis_volume 0.038 0.341    
  
6. Univariate analysis – AIBL dataset – HC vs AD 
Supplementary Table 5 - Statistical significance measured by the Mann-Whitney U test and effect 
size measured by Cliff’s delta absolute value based on the comparison of the reconstruction error 
for each brain region between the HC and the AD groups from AIBL dataset. The regions with p-
value <= 0.05 are highlighted in bold. 
Regions Effect size p-value Regions Effect size p-value 
Left-Lateral-Ventricle -0.584 >0.001 lh_parstriangularis_volume 0.275 0.003 
Left-Inf-Lat-Vent -0.803 >0.001 lh_pericalcarine_volume 0.133 0.092 
Left-Cerebellum-White-Matter 0.224 0.013 lh_postcentral_volume 0.137 0.086 
Left-Cerebellum-Cortex 0.307 0.001 lh_posteriorcingulate_volume 0.416 0.000 
Left-Thalamus-Proper 0.335 >0.001 lh_precentral_volume 0.075 0.228 
Left-Caudate 0.147 0.072 lh_precuneus_volume 0.721 >0.001 
Left-Putamen 0.284 0.002 lh_rostralanteriorcingulate_volume 0.387 >0.001 
Left-Pallidum 0.151 0.066 lh_rostralmiddlefrontal_volume 0.510 >0.001 
3rd-Ventricle -0.510 >0.001 lh_superiorfrontal_volume 0.326 0.001 
4th-Ventricle -0.079 0.216 lh_superiorparietal_volume 0.447 >0.001 
Brain-Stem 0.197 0.025 lh_superiortemporal_volume 0.481 >0.001 
Left-Hippocampus 0.729 >0.001 lh_supramarginal_volume 0.382 >0.001 
Left-Amygdala 0.666 >0.001 lh_frontalpole_volume 0.184 0.034 
CSF -0.492 >0.001 lh_temporalpole_volume 0.238 0.009 
Left-Accumbens-area 0.217 0.015 lh_transversetemporal_volume 0.113 0.130 
Left-VentralDC 0.226 0.012 lh_insula_volume 0.272 0.003 
Right-Lateral-Ventricle -0.610 >0.001 rh_bankssts_volume 0.540 0.000 
Right-Inf-Lat-Vent -0.764 >0.001 rh_caudalanteriorcingulate_volume 0.241 0.008 
Right-Cerebellum-White-Matter 0.203 0.022 rh_caudalmiddlefrontal_volume 0.386 >0.001 
Right-Cerebellum-Cortex 0.313 0.001 rh_cuneus_volume 0.287 0.002 
Right-Thalamus-Proper 0.356 >0.001 rh_entorhinal_volume 0.734 >0.001 
Right-Caudate 0.151 0.067 rh_fusiform_volume 0.533 >0.001 
Right-Putamen 0.276 0.003 rh_inferiorparietal_volume 0.728 >0.001 
Right-Pallidum 0.141 0.080 rh_inferiortemporal_volume 0.720 >0.001 
Right-Hippocampus 0.751 >0.001 rh_isthmuscingulate_volume 0.595 >0.001 
Right-Amygdala 0.737 >0.001 rh_lateraloccipital_volume 0.485 >0.001 
Right-Accumbens-area 0.362 >0.001 rh_lateralorbitofrontal_volume 0.407 >0.001 
Right-VentralDC 0.270 0.004 rh_lingual_volume 0.339 >0.001 
CC_Posterior 0.070 0.244 rh_medialorbitofrontal_volume 0.340 >0.001 
CC_Mid_Posterior 0.307 0.001 rh_middletemporal_volume 0.609 >0.001 
CC_Central 0.393 >0.001 rh_parahippocampal_volume 0.576 >0.001 
CC_Mid_Anterior 0.427 >0.001 rh_paracentral_volume 0.103 0.153 
CC_Anterior 0.084 0.203 rh_parsopercularis_volume 0.305 0.001 
lh_bankssts_volume 0.389 >0.001 rh_parsorbitalis_volume 0.326 0.001 
lh_caudalanteriorcingulate_volume 0.045 0.326 rh_parstriangularis_volume 0.309 0.001 
lh_caudalmiddlefrontal_volume 0.312 0.001 rh_pericalcarine_volume 0.161 0.054 
lh_cuneus_volume 0.357 >0.001 rh_postcentral_volume 0.046 0.322 
lh_entorhinal_volume 0.719 >0.001 rh_posteriorcingulate_volume 0.360 >0.001 
lh_fusiform_volume 0.586 >0.001 rh_precentral_volume 0.074 0.231 
lh_inferiorparietal_volume 0.636 >0.001 rh_precuneus_volume 0.652 >0.001 
lh_inferiortemporal_volume 0.585 >0.001 rh_rostralanteriorcingulate_volume 0.388 >0.001 
lh_isthmuscingulate_volume 0.590 >0.001 rh_rostralmiddlefrontal_volume 0.469 >0.001 
lh_lateraloccipital_volume 0.589 >0.001 rh_superiorfrontal_volume 0.304 0.001 
lh_lateralorbitofrontal_volume 0.407 >0.001 rh_superiorparietal_volume 0.596 >0.001 
lh_lingual_volume 0.283 0.002 rh_superiortemporal_volume 0.441 >0.001 
lh_medialorbitofrontal_volume 0.214 0.016 rh_supramarginal_volume 0.496 >0.001 
lh_middletemporal_volume 0.624 >0.001 rh_frontalpole_volume 0.092 0.179 
lh_parahippocampal_volume 0.485 >0.001 rh_temporalpole_volume 0.381 >0.001 
lh_paracentral_volume 0.137 0.087 rh_transversetemporal_volume 0.219 0.014 
lh_parsopercularis_volume 0.365 >0.001 rh_insula_volume 0.439 >0.001 
lh_parsorbitalis_volume 0.256 0.005    
  
7. Univariate analysis – ARWIBO dataset – HC vs MCI 
Supplementary Table 6 - Statistical significance measured by the Mann-Whitney U test and effect 
size measured by Cliff’s delta absolute value based on the comparison of the reconstruction error 
for each brain region between the HC and the MCI groups from the ARWIBO dataset. The regions 
with p-value <= 0.05 are highlighted in bold. 
Regions Effect size p-value Regions Effect size p-value 
Left-Lateral-Ventricle -0.251 0.001 lh_parstriangularis_volume 0.199 0.007 
Left-Inf-Lat-Vent -0.250 0.001 lh_pericalcarine_volume -0.018 0.412 
Left-Cerebellum-White-Matter 0.167 0.020 lh_postcentral_volume 0.043 0.296 
Left-Cerebellum-Cortex -0.085 0.147 lh_posteriorcingulate_volume 0.236 0.002 
Left-Thalamus-Proper 0.210 0.005 lh_precentral_volume 0.145 0.036 
Left-Caudate 0.047 0.280 lh_precuneus_volume 0.229 0.002 
Left-Putamen 0.084 0.149 lh_rostralanteriorcingulate_volume 0.139 0.043 
Left-Pallidum 0.010 0.452 lh_rostralmiddlefrontal_volume 0.189 0.010 
3rd-Ventricle -0.235 0.002 lh_superiorfrontal_volume 0.226 0.003 
4th-Ventricle -0.170 0.018 lh_superiorparietal_volume 0.132 0.051 
Brain-Stem 0.148 0.034 lh_superiortemporal_volume -0.020 0.402 
Left-Hippocampus 0.276 >0.001 lh_supramarginal_volume 0.070 0.193 
Left-Amygdala 0.122 0.066 lh_frontalpole_volume -0.037 0.323 
CSF -0.285 >0.001 lh_temporalpole_volume 0.071 0.190 
Left-Accumbens-area 0.277 >0.001 lh_transversetemporal_volume -0.132 0.051 
Left-VentralDC 0.119 0.071 lh_insula_volume 0.185 0.011 
Right-Lateral-Ventricle -0.261 0.001 rh_bankssts_volume 0.247 0.001 
Right-Inf-Lat-Vent -0.335 >0.001 rh_caudalanteriorcingulate_volume 0.039 0.315 
Right-Cerebellum-White-Matter 0.037 0.325 rh_caudalmiddlefrontal_volume 0.243 0.001 
Right-Cerebellum-Cortex -0.048 0.276 rh_cuneus_volume -0.026 0.376 
Right-Thalamus-Proper 0.170 0.018 rh_entorhinal_volume 0.272 >0.001 
Right-Caudate 0.110 0.087 rh_fusiform_volume 0.306 >0.001 
Right-Putamen 0.095 0.121 rh_inferiorparietal_volume 0.271 >0.001 
Right-Pallidum 0.085 0.148 rh_inferiortemporal_volume 0.344 >0.001 
Right-Hippocampus 0.269 >0.001 rh_isthmuscingulate_volume 0.137 0.045 
Right-Amygdala 0.237 0.002 rh_lateraloccipital_volume 0.135 0.048 
Right-Accumbens-area 0.109 0.088 rh_lateralorbitofrontal_volume 0.195 0.008 
Right-VentralDC 0.106 0.095 rh_lingual_volume 0.165 0.021 
CC_Posterior 0.110 0.088 rh_medialorbitofrontal_volume 0.232 0.002 
CC_Mid_Posterior 0.120 0.069 rh_middletemporal_volume 0.228 0.002 
CC_Central 0.147 0.035 rh_parahippocampal_volume 0.228 0.002 
CC_Mid_Anterior 0.089 0.135 rh_paracentral_volume 0.166 0.020 
CC_Anterior 0.068 0.202 rh_parsopercularis_volume 0.098 0.114 
lh_bankssts_volume 0.085 0.146 rh_parsorbitalis_volume 0.181 0.013 
lh_caudalanteriorcingulate_volume 0.125 0.062 rh_parstriangularis_volume 0.168 0.019 
lh_caudalmiddlefrontal_volume 0.147 0.035 rh_pericalcarine_volume 0.093 0.126 
lh_cuneus_volume -0.025 0.378 rh_postcentral_volume -0.020 0.400 
lh_entorhinal_volume 0.203 0.006 rh_posteriorcingulate_volume 0.244 0.001 
lh_fusiform_volume 0.262 0.001 rh_precentral_volume 0.198 0.007 
lh_inferiorparietal_volume 0.198 0.007 rh_precuneus_volume 0.256 0.001 
lh_inferiortemporal_volume 0.275 >0.001 rh_rostralanteriorcingulate_volume 0.191 0.009 
lh_isthmuscingulate_volume 0.155 0.028 rh_rostralmiddlefrontal_volume 0.119 0.070 
lh_lateraloccipital_volume 0.176 0.015 rh_superiorfrontal_volume 0.261 0.001 
lh_lateralorbitofrontal_volume 0.193 0.009 rh_superiorparietal_volume 0.204 0.006 
lh_lingual_volume 0.175 0.015 rh_superiortemporal_volume 0.097 0.117 
lh_medialorbitofrontal_volume 0.253 0.001 rh_supramarginal_volume 0.131 0.053 
lh_middletemporal_volume 0.280 >0.001 rh_frontalpole_volume -0.023 0.389 
lh_parahippocampal_volume 0.325 >0.001 rh_temporalpole_volume 0.084 0.150 
lh_paracentral_volume 0.086 0.145 rh_transversetemporal_volume 0.048 0.276 
lh_parsopercularis_volume 0.163 0.022 rh_insula_volume 0.149 0.033 
lh_parsorbitalis_volume 0.209 0.005    
  
8. Univariate analysis – ARWIBO dataset – HC vs AD 
Supplementary Table 7 - Statistical significance measured by the Mann-Whitney U test and effect 
size measured by Cliff’s delta absolute value based on the comparison of the reconstruction error 
for each brain region between the HC and the AD groups from ARWIBO dataset. The regions 
with p-value <= 0.05 are highlighted in bold. 
Regions Effect size p-value Regions Effect size p-value 
Left-Lateral-Ventricle -0.547 >0.001 lh_parstriangularis_volume 0.233 0.012 
Left-Inf-Lat-Vent -0.758 >0.001 lh_pericalcarine_volume 0.080 0.220 
Left-Cerebellum-White-Matter 0.063 0.272 lh_postcentral_volume -0.123 0.117 
Left-Cerebellum-Cortex -0.017 0.435 lh_posteriorcingulate_volume 0.435 >0.001 
Left-Thalamus-Proper 0.282 0.003 lh_precentral_volume -0.029 0.391 
Left-Caudate 0.321 0.001 lh_precuneus_volume 0.599 >0.001 
Left-Putamen 0.287 0.003 lh_rostralanteriorcingulate_volume 0.289 0.003 
Left-Pallidum -0.156 0.065 lh_rostralmiddlefrontal_volume 0.373 >0.001 
3rd-Ventricle -0.517 >0.001 lh_superiorfrontal_volume 0.362 >0.001 
4th-Ventricle -0.050 0.314 lh_superiorparietal_volume 0.303 0.002 
Brain-Stem 0.126 0.112 lh_superiortemporal_volume 0.382 >0.001 
Left-Hippocampus 0.790 >0.001 lh_supramarginal_volume 0.342 >0.001 
Left-Amygdala 0.649 >0.001 lh_frontalpole_volume 0.211 0.020 
CSF -0.518 >0.001 lh_temporalpole_volume 0.477 >0.001 
Left-Accumbens-area 0.325 0.001 lh_transversetemporal_volume 0.216 0.018 
Left-VentralDC 0.138 0.091 lh_insula_volume 0.510 >0.001 
Right-Lateral-Ventricle -0.478 >0.001 rh_bankssts_volume 0.486 >0.001 
Right-Inf-Lat-Vent -0.768 >0.001 rh_caudalanteriorcingulate_volume 0.042 0.342 
Right-Cerebellum-White-Matter 0.098 0.170 rh_caudalmiddlefrontal_volume 0.129 0.105 
Right-Cerebellum-Cortex -0.024 0.409 rh_cuneus_volume -0.009 0.467 
Right-Thalamus-Proper 0.117 0.129 rh_entorhinal_volume 0.603 >0.001 
Right-Caudate 0.301 0.002 rh_fusiform_volume 0.506 >0.001 
Right-Putamen 0.272 0.004 rh_inferiorparietal_volume 0.599 >0.001 
Right-Pallidum -0.042 0.344 rh_inferiortemporal_volume 0.415 >0.001 
Right-Hippocampus 0.635 >0.001 rh_isthmuscingulate_volume 0.370 >0.001 
Right-Amygdala 0.651 >0.001 rh_lateraloccipital_volume 0.397 >0.001 
Right-Accumbens-area 0.309 0.001 rh_lateralorbitofrontal_volume 0.305 0.002 
Right-VentralDC 0.093 0.184 rh_lingual_volume 0.331 0.001 
CC_Posterior 0.155 0.066 rh_medialorbitofrontal_volume 0.303 0.002 
CC_Mid_Posterior 0.008 0.469 rh_middletemporal_volume 0.519 >0.001 
CC_Central 0.258 0.006 rh_parahippocampal_volume 0.326 0.001 
CC_Mid_Anterior 0.289 0.002 rh_paracentral_volume 0.114 0.135 
CC_Anterior 0.041 0.345 rh_parsopercularis_volume 0.088 0.197 
lh_bankssts_volume 0.394 0.000 rh_parsorbitalis_volume 0.325 0.001 
lh_caudalanteriorcingulate_volume 0.037 0.361 rh_parstriangularis_volume 0.201 0.026 
lh_caudalmiddlefrontal_volume 0.352 >0.001 rh_pericalcarine_volume 0.061 0.276 
lh_cuneus_volume 0.037 0.361 rh_postcentral_volume -0.147 0.077 
lh_entorhinal_volume 0.633 >0.001 rh_posteriorcingulate_volume 0.340 >0.001 
lh_fusiform_volume 0.657 >0.001 rh_precentral_volume -0.022 0.417 
lh_inferiorparietal_volume 0.526 >0.001 rh_precuneus_volume 0.570 >0.001 
lh_inferiortemporal_volume 0.553 >0.001 rh_rostralanteriorcingulate_volume 0.240 0.010 
lh_isthmuscingulate_volume 0.344 >0.001 rh_rostralmiddlefrontal_volume 0.304 0.002 
lh_lateraloccipital_volume 0.322 0.001 rh_superiorfrontal_volume 0.330 0.001 
lh_lateralorbitofrontal_volume 0.325 0.001 rh_superiorparietal_volume 0.410 >0.001 
lh_lingual_volume 0.302 0.002 rh_superiortemporal_volume 0.350 >0.001 
lh_medialorbitofrontal_volume 0.205 0.024 rh_supramarginal_volume 0.380 >0.001 
lh_middletemporal_volume 0.543 >0.001 rh_frontalpole_volume 0.136 0.094 
lh_parahippocampal_volume 0.501 >0.001 rh_temporalpole_volume 0.365 >0.001 
lh_paracentral_volume -0.002 0.493 rh_transversetemporal_volume 0.141 0.085 
lh_parsopercularis_volume 0.259 0.006 rh_insula_volume 0.426 >0.001 
lh_parsorbitalis_volume 0.422 >0.001    
  
9. Univariate analysis – OASIS-1 dataset – HC vs AD 
Supplementary Table 8 - Statistical significance measured by the Mann-Whitney U test and effect 
size measured by Cliff’s delta absolute value based on the comparison of the reconstruction error 
for each brain region between the HC and the AD groups from the OASIS-1 dataset. The regions 
with p-value <= 0.05 are highlighted in bold. 
Regions Effect size p-value Regions Effect size p-value 
Left-Lateral-Ventricle -0.469 >0.001 lh_parstriangularis_volume 0.118 0.187 
Left-Inf-Lat-Vent -0.735 >0.001 lh_pericalcarine_volume -0.010 0.472 
Left-Cerebellum-White-Matter 0.218 0.049 lh_postcentral_volume 0.362 0.003 
Left-Cerebellum-Cortex 0.287 0.015 lh_posteriorcingulate_volume 0.359 0.003 
Left-Thalamus-Proper 0.492 >0.001 lh_precentral_volume 0.330 0.006 
Left-Caudate 0.040 0.382 lh_precuneus_volume 0.434 0.000 
Left-Putamen 0.210 0.056 lh_rostralanteriorcingulate_volume 0.102 0.221 
Left-Pallidum 0.030 0.413 lh_rostralmiddlefrontal_volume 0.337 0.005 
3rd-Ventricle -0.457 >0.001 lh_superiorfrontal_volume 0.358 0.003 
4th-Ventricle 0.006 0.484 lh_superiorparietal_volume 0.313 0.009 
Brain-Stem 0.334 0.006 lh_superiortemporal_volume 0.502 >0.001 
Left-Hippocampus 0.494 >0.001 lh_supramarginal_volume 0.502 >0.001 
Left-Amygdala 0.481 >0.001 lh_frontalpole_volume 0.151 0.127 
CSF -0.350 0.004 lh_temporalpole_volume 0.032 0.405 
Left-Accumbens-area 0.375 0.002 lh_transversetemporal_volume 0.343 0.005 
Left-VentralDC 0.275 0.019 lh_insula_volume 0.313 0.009 
Right-Lateral-Ventricle -0.516 >0.001 rh_bankssts_volume 0.644 >0.001 
Right-Inf-Lat-Vent -0.780 >0.001 rh_caudalanteriorcingulate_volume 0.027 0.421 
Right-Cerebellum-White-Matter 0.150 0.129 rh_caudalmiddlefrontal_volume 0.387 0.002 
Right-Cerebellum-Cortex 0.227 0.043 rh_cuneus_volume 0.151 0.127 
Right-Thalamus-Proper 0.521 >0.001 rh_entorhinal_volume 0.566 >0.001 
Right-Caudate 0.002 0.496 rh_fusiform_volume 0.511 >0.001 
Right-Putamen 0.339 0.005 rh_inferiorparietal_volume 0.462 >0.001 
Right-Pallidum 0.007 0.480 rh_inferiortemporal_volume 0.572 >0.001 
Right-Hippocampus 0.623 >0.001 rh_isthmuscingulate_volume 0.274 0.019 
Right-Amygdala 0.541 >0.001 rh_lateraloccipital_volume 0.249 0.030 
Right-Accumbens-area 0.424 0.001 rh_lateralorbitofrontal_volume 0.243 0.033 
Right-VentralDC 0.354 0.004 rh_lingual_volume 0.313 0.009 
CC_Posterior 0.183 0.084 rh_medialorbitofrontal_volume 0.312 0.009 
CC_Mid_Posterior 0.496 >0.001 rh_middletemporal_volume 0.499 >0.001 
CC_Central 0.503 >0.001 rh_parahippocampal_volume 0.430 0.001 
CC_Mid_Anterior 0.432 0.001 rh_paracentral_volume 0.234 0.038 
CC_Anterior 0.375 0.002 rh_parsopercularis_volume 0.297 0.012 
lh_bankssts_volume 0.428 0.001 rh_parsorbitalis_volume 0.283 0.016 
lh_caudalanteriorcingulate_volume 0.011 0.468 rh_parstriangularis_volume 0.283 0.016 
lh_caudalmiddlefrontal_volume 0.113 0.198 rh_pericalcarine_volume 0.074 0.288 
lh_cuneus_volume 0.200 0.065 rh_postcentral_volume 0.379 0.002 
lh_entorhinal_volume 0.339 0.005 rh_posteriorcingulate_volume 0.183 0.084 
lh_fusiform_volume 0.375 0.002 rh_precentral_volume 0.428 0.001 
lh_inferiorparietal_volume 0.452 >0.001 rh_precuneus_volume 0.368 0.003 
lh_inferiortemporal_volume 0.456 >0.001 rh_rostralanteriorcingulate_volume 0.114 0.195 
lh_isthmuscingulate_volume 0.444 >0.001 rh_rostralmiddlefrontal_volume 0.425 0.001 
lh_lateraloccipital_volume 0.314 0.009 rh_superiorfrontal_volume 0.425 0.001 
lh_lateralorbitofrontal_volume 0.354 0.004 rh_superiorparietal_volume 0.272 0.020 
lh_lingual_volume 0.238 0.036 rh_superiortemporal_volume 0.548 >0.001 
lh_medialorbitofrontal_volume 0.064 0.316 rh_supramarginal_volume 0.519 >0.001 
lh_middletemporal_volume 0.507 >0.001 rh_frontalpole_volume 0.126 0.171 
lh_parahippocampal_volume 0.458 >0.001 rh_temporalpole_volume 0.007 0.480 
lh_paracentral_volume 0.333 0.006 rh_transversetemporal_volume 0.413 0.001 
lh_parsopercularis_volume 0.245 0.032 rh_insula_volume 0.292 0.014 
lh_parsorbitalis_volume 0.270 0.021    
  
10. Univariate analysis –MIRIAD dataset – HC vs AD 
Supplementary Table 9 - Statistical significance measured by the Mann-Whitney U test and effect 
size measured by Cliff’s delta absolute value based on the comparison of the reconstruction error 
for each brain region between the HC and the AD groups from the MIRIAD dataset. The regions 
with p-value <= 0.05 are highlighted in bold. 
Regions Effect size p-value Regions Effect size p-value 
Left-Lateral-Ventricle -0.630 >0.001 lh_parstriangularis_volume 0.034 0.361 
Left-Inf-Lat-Vent -0.964 >0.001 lh_pericalcarine_volume -0.073 0.222 
Left-Cerebellum-White-Matter 0.022 0.411 lh_postcentral_volume 0.394 >0.001 
Left-Cerebellum-Cortex 0.396 >0.001 lh_posteriorcingulate_volume 0.545 >0.001 
Left-Thalamus-Proper 0.470 >0.001 lh_precentral_volume 0.430 >0.001 
Left-Caudate 0.338 >0.001 lh_precuneus_volume 0.841 >0.001 
Left-Putamen 0.386 >0.001 lh_rostralanteriorcingulate_volume 0.440 >0.001 
Left-Pallidum 0.092 0.169 lh_rostralmiddlefrontal_volume 0.836 >0.001 
3rd-Ventricle -0.385 >0.001 lh_superiorfrontal_volume 0.856 >0.001 
4th-Ventricle 0.059 0.269 lh_superiorparietal_volume 0.741 >0.001 
Brain-Stem 0.334 >0.001 lh_superiortemporal_volume 0.753 >0.001 
Left-Hippocampus 0.780 >0.001 lh_supramarginal_volume 0.788 >0.001 
Left-Amygdala 0.878 >0.001 lh_frontalpole_volume 0.180 0.030 
CSF -0.673 >0.001 lh_temporalpole_volume 0.367 >0.001 
Left-Accumbens-area 0.526 >0.001 lh_transversetemporal_volume 0.532 >0.001 
Left-VentralDC 0.315 >0.001 lh_insula_volume 0.542 >0.001 
Right-Lateral-Ventricle -0.723 >0.001 rh_bankssts_volume 0.641 >0.001 
Right-Inf-Lat-Vent -0.932 >0.001 rh_caudalanteriorcingulate_volume 0.374 >0.001 
Right-Cerebellum-White-Matter 0.131 0.086 rh_caudalmiddlefrontal_volume 0.471 >0.001 
Right-Cerebellum-Cortex 0.418 >0.001 rh_cuneus_volume 0.430 >0.001 
Right-Thalamus-Proper 0.416 >0.001 rh_entorhinal_volume 0.593 >0.001 
Right-Caudate 0.183 0.028 rh_fusiform_volume 0.819 >0.001 
Right-Putamen 0.406 >0.001 rh_inferiorparietal_volume 0.807 >0.001 
Right-Pallidum 0.060 0.265 rh_inferiortemporal_volume 0.804 >0.001 
Right-Hippocampus 0.802 >0.001 rh_isthmuscingulate_volume 0.712 >0.001 
Right-Amygdala 0.877 >0.001 rh_lateraloccipital_volume 0.457 >0.001 
Right-Accumbens-area 0.558 >0.001 rh_lateralorbitofrontal_volume 0.547 >0.001 
Right-VentralDC 0.422 >0.001 rh_lingual_volume 0.396 >0.001 
CC_Posterior 0.110 0.125 rh_medialorbitofrontal_volume 0.481 >0.001 
CC_Mid_Posterior -0.067 0.244 rh_middletemporal_volume 0.825 >0.001 
CC_Central 0.411 >0.001 rh_parahippocampal_volume 0.488 >0.001 
CC_Mid_Anterior 0.500 >0.001 rh_paracentral_volume 0.150 0.058 
CC_Anterior 0.083 0.193 rh_parsopercularis_volume 0.363 >0.001 
lh_bankssts_volume 0.791 >0.001 rh_parsorbitalis_volume 0.232 0.008 
lh_caudalanteriorcingulate_volume -0.095 0.162 rh_parstriangularis_volume -0.110 0.126 
lh_caudalmiddlefrontal_volume 0.643 >0.001 rh_pericalcarine_volume 0.046 0.315 
lh_cuneus_volume 0.156 0.052 rh_postcentral_volume 0.238 0.006 
lh_entorhinal_volume 0.446 >0.001 rh_posteriorcingulate_volume 0.575 >0.001 
lh_fusiform_volume 0.818 >0.001 rh_precentral_volume 0.424 >0.001 
lh_inferiorparietal_volume 0.869 >0.001 rh_precuneus_volume 0.913 >0.001 
lh_inferiortemporal_volume 0.884 >0.001 rh_rostralanteriorcingulate_volume 0.245 0.005 
lh_isthmuscingulate_volume 0.604 >0.001 rh_rostralmiddlefrontal_volume 0.804 >0.001 
lh_lateraloccipital_volume 0.628 >0.001 rh_superiorfrontal_volume 0.686 >0.001 
lh_lateralorbitofrontal_volume 0.601 >0.001 rh_superiorparietal_volume 0.812 >0.001 
lh_lingual_volume 0.304 0.001 rh_superiortemporal_volume 0.645 >0.001 
lh_medialorbitofrontal_volume 0.535 >0.001 rh_supramarginal_volume 0.857 >0.001 
lh_middletemporal_volume 0.882 >0.001 rh_frontalpole_volume 0.216 0.012 
lh_parahippocampal_volume 0.140 0.072 rh_temporalpole_volume 0.437 >0.001 
lh_paracentral_volume 0.381 >0.001 rh_transversetemporal_volume 0.393 >0.001 
lh_parsopercularis_volume 0.314 0.001 rh_insula_volume 0.717 >0.001 
lh_parsorbitalis_volume 0.333 >0.001    
  
11. Region importance – ADNI dataset – HC vs EMCI 
 
Supplementary Figure 1 - Regional deviations of the EMCI group from the ADNI dataset. The 
marker indicates the mean effect size between the HC and the EMCI groups. The horizontal bars 




12. Region importance – ADNI dataset – HC vs LMCI 
 
Supplementary Figure 2 – Regional deviations of the LMCI group from the ADNI dataset. The 
marker indicates the mean effect size between the HC and the LMCI groups. The horizontal bars 
indicate the 95% confidence interval calculated using the percentile method on the bootstrap 
analysis. 
  
13. Region importance – ADNI dataset – HC vs AD 
 
Supplementary Figure 3 – Regional deviations of the AD group from the ADNI dataset. The 
marker indicates the mean effect size between the HC and the AD groups. The horizontal bars 
indicate the 95% confidence interval calculated using the percentile method on the bootstrap 
analysis. 
14. Region importance – AIBL dataset – HC vs MCI 
 
Supplementary Figure 4 – Regional deviations of the MCI group from the AIBL dataset. The 
marker indicates the mean effect size between the HC and the MCI groups. The horizontal bars 
indicate the 95% confidence interval calculated using the percentile method on the bootstrap 
analysis. 
 
15. Region importance – AIBL dataset – HC vs AD 
 
Supplementary Figure 5 – Regional deviations of the AD group from the AIBL dataset. The marker 
indicates the mean effect size between the HC and the AD groups. The horizontal bars indicate 
the 95% confidence interval calculated using the percentile method on the bootstrap analysis. 
  
16. Region importance – ARWIBO dataset – HC vs MCI 
 
Supplementary Figure 6 - Regional deviations of the MCI group from the ARWIBO dataset. The 
marker indicates the mean effect size between the HC and the MCI groups. The horizontal bars 
indicate the 95% confidence interval calculated using the percentile method on the bootstrap 
analysis. 
  
17. Region importance – ARWIBO dataset – HC vs AD 
 
Supplementary Figure 7 – Regional deviations of the AD group from the ARWIBO dataset. The 
marker indicates the mean effect size between the HC and the AD groups. The horizontal bars 




18. Region importance – OASIS-1 dataset – HC vs AD 
 
Supplementary Figure 8 - Regional deviations of the AD group from the OASIS-1 dataset. The 
marker indicates the mean effect size between the HC and the AD groups. The horizontal bars 




19. Region importance – MIRIAD dataset – HC vs AD 
 
Supplementary Figure 9 - Regional deviations of the AD group from the MIRIAD dataset. The 
marker indicates the mean effect size between the HC and the AD groups. The horizontal bars 
indicate the 95% confidence interval calculated using the percentile method on the bootstrap 
analysis. 
  
20. Comparison of deviation values for healthy controls and 
patients - confidence interval of the differences 
 
When we analysed the confidence interval of the difference between 
groups in the observed deviation, we obtained that, for the ADNI dataset, the 
difference between HC and EMCI was in the range [-0.03, 0.00], the difference 
between HC and LMCI was in the range [-0.06, -0.03], the difference between 
HC and AD group was in the interval of [-0.16, -0.06], the difference between 
EMCI and LMCI was in the range [-0.03, -0.02], the difference between EMCI and 
AD was in the range [-0.14, -0.06], and the difference between LMCI and AD was 
in the range [-0.10, -0.03]. For the AIBL dataset, the difference between HC and 
MCI was in the range [-0.09, -0.05], the difference between HC and AD was in 
the range [-0.17, -0.07], the difference between MCI and AD was in the range [-
0.09, 0.00]. For the ARWiBo dataset, the difference between HC and MCI was in 
the range [-0.08, -0.03], the difference between HC and AD was in the range [-
0.24, -0.10], the difference between MCI and AD was in the range [-0.16, -0.06]. 
For the OASIS-1 dataset, the difference between HC and AD was in the range [-
0.18, -0.33]. Finally, for the MIRIAD dataset, the difference between HC and AD 
was in the range [-0.16, -0.41]. In summary, the five independent datasets 
presented mean deviation scores significantly different between their groups, 
except the comparison between HC and EMCI in the ADNI dataset and the 
comparison between MCI and AD in the AIBL dataset. 
  
21. Traditional machine learning classification - confidence 
interval of the differences 
 
To identify significant differences between the performance of the 
normative models and traditional classifiers, we calculated the confidence interval 
(95% of confidence) of the difference in AUC between the two methods. For the 
ADNI dataset we found that when classifying HC and EMCI the difference was in 
the range [-0.28, -0.09], when classifying HC and LMCI the difference was in the 
range [-0.24, -0.04], and when classifying HC and AD the difference was in the 
range [-0.25, -0.12]. For the AIBL dataset, when classifying the HC and MCI the 
difference of performance was in the range [-0.17, 0.74], and when classifying 
HC and AD the difference was in the range [-0.29, -0.12]. For the ARWiBo 
dataset, when classifying the HC and MCI the difference of performance was in 
the range [-0.15, 0.12], and when classifying HC and AD the difference was in 
the range [-0.17, 0.00]. For the OASIS-1 dataset, when classifying HC and AD 
the difference was in the range [-0.25, 0.04]. Finally, For the MIRIAD dataset, 
when classifying HC and AD the difference was in the range [-0.15, 0.06]. In 
summary, the traditional classifiers were superior to the normative models when 
predicting the difference between the groups in the ADNI dataset and the 
difference between HC and AD for the AIBL dataset; in contrast the performance 
of the two approaches was comparable for all other comparisons. 
